TY - JOUR T1 - Antibody Engineering for Nuclear Imaging and Radioimmunotherapy JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1316 LP - 1322 DO - 10.2967/jnumed.122.263861 VL - 63 IS - 9 AU - Cindy Rodriguez AU - Samantha Delaney AU - Samantha M. Sarrett AU - Outi M. Keinänen AU - Brian M. Zeglis Y1 - 2022/09/01 UR - http://jnm.snmjournals.org/content/63/9/1316.abstract N2 - Radiolabeled antibodies have become indispensable tools in nuclear medicine. However, the natural roles of antibodies within the immune system mean that they have several intrinsic limitations as a platform for radiopharmaceuticals. In recent years, the field has increasingly turned to antibody engineering to circumvent these issues while retaining the manifold benefits of the immunoglobulin framework. In this “Focus on Molecular Imaging” review, we cover recent advances in the application of antibody engineering to immunoPET, immunoSPECT, and radioimmunotherapy. Specifically, we address how antibody engineering has been used to improve radioimmunoconjugates on four fronts: optimizing pharmacokinetics, facilitating site-specific bioconjugation, modulating Fc interactions, and creating bispecific constructs. ER -